Rresearch programme: T-cell therapeutics - Genocea/University of Minnesota
Latest Information Update: 27 Mar 2023
At a glance
- Originator Genocea Biosciences; University of Minnesota
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer